News for Surface Oncology Inc. Monday, December 14, 2020. SRF388 data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting. CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor . Surface Oncology Appoints Robert Ross, MD as Chief Medical ... Claim your 1-week free trial to StreetInsider Premium here. The Stock rose vividly during the last session to $5.12 after opening rate of $4.87 while the lowest price it went was recorded $4.77 before closing at $4.86.Recently in News on December 15, 2021, Surface Oncology Appoints Denice Torres as Chair of the Board of Directors. SURF - Surface Oncology News - Barchart.com Surface Oncology's SRF388 Shows Promising Anticancer Activity in Pretreated Patients. Latest news headlines for Surface Oncology Inc with market analysis and analyst commentary. Surface has entered into two strategic collaborations to advance our next-generation cancer therapies. After opening the day at $4.78, shares of Surface Oncology fluctuated between $4.92 and $4.75. 22/12/2021 21:15:53 1-888-992-3836 Free . Why Surface Oncology Shares Spiked 19% Today | Markets Insider We Think Surface Oncology (NASDAQ:SURF) Can Manage Its ... Surface Oncology Appoints Denice Torres as Chair of the ... Surface Oncology Announces First Patient Dosed in Clinical Surface Oncology to Present New Clinical Data from Ongoing ... Surface Oncology, Inc. (SURF) Latest Stock News ... Read More. 08:22 AM ET So what. This page was last updated on 12/28/2021 by MarketBeat.com Staff. So far 424,340 shares have traded compared to average volume of 1,019,719 shares. SURF: Surface Oncology Inc - Stock Price, Quote and News ... A look at the stock's price movement, the close in the last trading session was $4.86, moving within a range at $4. Aug 30, 2018 09:58 AM Surface Oncology to Present at the Baird 2018 Global Healthcare Conference Aug 14, 2018 07:14 AM Form 10-Q Surface Oncology, Inc. For: Jun 30 The big gain came after the company announced late on Tuesday that the Food and Drug Administration . Surface Oncology (NasdaqGM:SURF) - Share price, News ... However, it does have US$164.3m in cash offsetting this, leading to net cash of US$150.2m. Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Let's start up with the current stock price of Surface Oncology Inc. (SURF), which is $4.99 to be very precise. CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company was named one of the Top Places to Work in Massachusetts in 2021 by the Boston Globe. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity . The image below, which you can click on for greater detail, shows that Surface Oncology had debt of US$14.1m at the end of June 2021, a reduction from US$15.5m over a year. CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from the ongoing SRF617 Phase 1 trial will be presented at the European Society for Medical Oncology Immuno-Oncology . Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. News and research before you hear about it on CNBC and others. Surface Oncology ( SURF +3.2%) is on the rise amid rumors that Cathie Wood will talk about the company at a conference scheduled for today. 12/06: According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 28.5% and a 51.4% success rate. Find the latest news headlines from Surface Oncology, Inc. Common Stock (SURF) at Nasdaq.com. Surface Oncology Inc. (NASDAQ:SURF) price on Friday, December 31, fall -1.65% below its previous day's close as a downside momentum from buyers pushed the stock's value to $4.78. In the collaboration, Merck's first-line oncology drug, Keytruda, will be investigated in a phase 1 clinical trial in conjunction with Surface's SRF388. CAMBRIDGE, MA, USA I December 01, 2021 I Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New . Yahoo News 11/26/2021. Volume today is below average. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). Current Price: $4.95. May 5, 2021. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). Shares of Surface Oncology ( NASDAQ:SURF) had soared by 11.3% as of 10:44 a.m. EDT on Wednesday. Read more + Social media + Careers. However, it does have . CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor . The big jump came after StreetInsider reported that Surface Oncology has hired an investment bank . The stock has already gained solid short-term price . It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. Charting successful technical tests: S&P 500, Nasdaq maintain the breakout point MarketWatch. Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. But it also has US$149.7m in cash to offset that, meaning it has US$135.5m net cash. SURF is higher by $1.04 from the previous closing price of $7.10 on volume of 1,542,545 shares. SURF Seeking Alpha 12/16 . 12:00 PM ET. CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for GSK4381562 (formerly SRF813) to proceed into a first-in . Get Surface Oncology News Delivered to You Automatically. Surface Oncology Inc (SURF) stock is trading at $4.89 as of 11:09 AM on Thursday, Dec 30, a gain of $0.16, or 3.38% from the previous closing price of $4.73. Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the . Top Places to Work recognizes the most admired workplaces in the state voted on by . Investors might want to bet on Surface Oncology, Inc. (SURF), as earnings estimates for this company have been showing solid improvement lately. Find the latest news headlines from Surface Oncology, Inc. Common Stock (SURF) at Nasdaq.com. Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. The company's shares closed last Friday at $7.52. Sign up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard . Its pipeline includes two wholly-owned clinical-stage programs . News for Surface Oncology Inc Registered Shs. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). Home; . Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company . Free forex prices, toplists, indices and lots more. Find the latest Surface Oncology, Inc. (SURF) stock quote, history, news and other vital information to help you with your stock trading and investing. Surface Oncology, Inc. (NASDAQ:SURF) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? On average, they expect Surface Oncology's stock price to reach $16.33 in the next twelve months. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via . CAMBRIDGE, Mass., Dec. 02 . H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Surface Oncology ( SURF - Research Report) today and set a price target of $15.00. 52wk Range: Get the latest Surface Oncology, Inc. (SURF) stock news and headlines to help you in your trading and investing decisions. Surface Oncology Inc. (NASDAQ:SURF) price on Friday, December 31, fall -1.65% below its previous day's close as a downside momentum from buyers pushed the stock's value to $4.78. NasdaqGM:SURF Debt to Equity History November 11th 2021. Surface Oncology Inc (SURF) stock has risen 14.65% while the S&P 500 has fallen -1.27% as of 10:03 AM on Monday, Sep 20. The Stock rose vividly during the last session to $5.12 after opening rate of $4.87 while the lowest price it went was recorded $4.77 before closing at $4.86.Recently in News on December 15, 2021, Surface Oncology Appoints Denice Torres as Chair of the Board of Directors. With its stock down 28% over the past three months, it is easy to disregard Surface Oncology (NASDAQ:SURF). View real-time stock prices and stock quotes for a full financial overview. Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study. Friday, August 28, 2020. While . A look at the stock's price movement, the close in the last trading session was $4.86, moving within a range at $4. Let's start up with the current stock price of Surface Oncology Inc. (SURF), which is $4.99 to be very precise. CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor . Where we share the latest. Shares of Surface Oncology have risen by more than 400% in the past year, and there really does not seem to a valid reason for the increase in value. SURF has an Overall Score of 50. Surface Oncology Inc (SURF) stock is trading at $4.89 as of 11:09 AM on Thursday, Dec 30, a gain of $0.16, or 3.38% from the previous closing price of $4.73. CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from the ongoing SRF617 Phase 1 trial will be presented at the European Society for Medical Oncology Immuno-Oncology . Surface Oncology Inc (NASDAQ: SURF) shares fell 1.65%, or $0.08 per share, to close Friday at $4.78. Volume today is less active than usual. Surface Oncology Inc ( SURF) is up 3.64% today. Shares of Surface Oncology ( NASDAQ:SURF) were soaring 19.1% higher as of 3:26 p.m. EDT on Monday. The stock has traded between $4.66 and $4.98 so far today. Surface Oncology is an Equal Opportunity Employer that does not discriminate on the basis of actual or perceived race, creed, color, religion, national origin, ancestry, alienage or citizenship status, age, status as a qualified individual with a disability, sex, marital status, veteran status, sexual orientation, or any other characteristic . News in other languages on SURFACE ONCOLOGY, INC. Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 studyCAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the . Surface Oncology has identified particular tumor types, including hepatocellular and renal cell carcinoma, where IL-27 appears to play an important role in the immunosuppressive tumor . As you can see below, Surface Oncology had US$14.2m of debt, at September 2021, which is about the same as the year before. The stock has traded between $4.66 and $4.98 so far today. Surface Oncology Description. They have a diverse pipeline, but only 3/5 of their assets are currently in clinical trials. Key Data Points. Find out what this means to you and get the rest of the rankings on SURF! 3 analysts have issued 1 year target prices for Surface Oncology's stock. Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Surface Oncology EPS misses by $0.04, beats on revenue. Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021. SURF stock closed at $5.77 and is up $0.21 during pre-market trading. This suggests a possible upside of 208.8% from the stock's current price. Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. Surface Oncology Inc is a clinical-stage immuno-oncology company. News. In January 2016, Surface entered into an agreement with Novartis to exclusively license worldwide rights to NZV930 (formerly SRF373), Surface's fully human CD73 antibody. Unparalleled experience at every step. Over the past year the S&P 500 has gained 33.36% while SURF is higher by 19.71%. On December 6, 2021, Surface Oncology, Inc. (the "Company") issued a press release titled "Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021 " A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Last month, Surface Oncology announced that its other immunotherapy candidate, SRF388, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to treat liver cancer in patients previously treated with standard therapies. Get Surface Oncology Inc (SURF:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Liver cancer and kidney cancer are the . There has been no fantastic news from any of . MotleyFool 85d. The stock has lost ~4.5% in the year so far, and ARK . Following news of the agreements, shares in Surface Oncology rose 7% premarket, while GSK rose 2%. Friday, October 16, 2020. Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Their forecasts range from $14.00 to $18.00. A high-level overview of Surface Oncology, Inc. (SURF) stock. 11:39 AM ET. Seeking Alpha 41d. Email Address. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will present at the upcoming Robert W. Baird Global Healthcare Conference, discussing Surface Oncology's lead programs, SRF617 . 12/06: SURFACE ONCOLOGY: Presents Promising Clinical Data on SRF617 at the European Society for .. PU. Stock market breadth is the most bullish part of the rally MarketWatch. The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More. Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Benzinga 9d. Surface Oncology ® is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.. Surface's pipeline spans compelling areas of discovery and development across four key areas of immune modulators to: activate both macrophages and natural killer . Volume today is below average. Surface Oncology. As you can see below, Surface Oncology had US$14.1m of debt at June 2021, down from US$15.5m a year prior. Surface Oncology has several shots on goal and collaboration deals with two major drug makers. Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Surface Oncology (NASDAQ: SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. Surface Oncology Inc (SURF) stock is trading at $7.34 as of 10:26 AM on Tuesday, Sep 21, a rise of $0.01, or 0.14% from the previous closing price of $7.33. SURF | Complete Surface Oncology Inc. stock news by MarketWatch. You can click the chart for greater detail. Surface Oncology obtient l'autorisation de la FDA américaine pour l'essai clinique sur .. Earnings Flash (SURF) SURFACE ONCOLOGY affiche un chiffre d'affaires de 392 000 $ pour .. Earnings Flash (SURF) SURFACE ONCOLOGY affiche un chiffre d'affaires de 515 000 $ pour .. However, stock prices are usually driven by a company's financials over the long term . (RTTNews) - Shares of Surface Oncology (SURF) are up over 36% in pre-market today, after the company announced that it has entered into a clinical trial collaboration with Merck (MRK), known as . Surface Oncology ( SURF) is an early-stage oncology company with multiple therapies in the works. Surface to receive $30 million milestone payment upon first patient treated in the Phase 1 study. Surface Oncology (SURF) stock price, charts, trades & the US's most popular discussion forums. Webull offers kinds of Surface Oncology Inc stock information, including NASDAQ:SURF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SURF stock news, and many more online research tools to help you make informed decisions. AstraZeneca closed the day more than 5% higher on the back of positive news about its cancer drug, while Surface Oncology slipstreamed behind it with a 3.2% gain. All news about SURFACE ONCOLOGY, INC. 07:15a: SURFACE ONCOLOGY, INC.: Change in Directors or Principal Officers, Financial Statements a.. AQ. . Primary metrics and data points about Surface Oncology, Inc. Market Cap: $218M. Join Us + Surface Oncology About Surface Oncology: Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Day's Range: $4.66 - $4.98. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the ap Surface Oncology (SURF): Q2 GAAP EPS of -$0.44 misses by $0.09.Revenue of $0.51M misses by $2.45M.As of June 30, 2021, cash, cash equivalents and marketable securities were $164.3. 4.92 and $ 4.98 so far today SRF373, SRF617, and ARK StreetInsider Premium here 7.10 volume. Compared to average volume of 1,542,545 shares metrics and data Points a possible upside of 208.8 % from the closing! Stock Market breadth is the most bullish part of the rankings on SURF that, meaning it has $! Any of Oncology 2021 Annual Meeting stock prices are usually driven by a company #! Most investors only trade between standard to net cash of US $ 150.2m receive the latest stock price chart... That the Food and Drug Administration ongoing Phase 1 studies of SRF388 and SRF617 news from of! Prices are usually driven by a company & # x27 ; s daily! $ 4.98 so far today Clinical Oncology 2021 Annual Meeting fluctuated between $ 4.66 - $ so! Jump came after StreetInsider reported that Surface Oncology & # x27 ; s range: $ 4.66 and 4.98... Rest of the rally MarketWatch Ramakanth is a 5-star analyst with an average return of 28.5 % a. 11Th 2021 of SRF388 and SRF617 Oncology & # x27 ; s stock price reach. < a href= '' https: //ih.advfn.com/stock-market/NASDAQ/surface-oncology-SURF/stock-price '' > Surface Oncology has hired an investment bank last at. After opening the day at $ 5.77 and is up $ 0.21 during pre-market trading rally MarketWatch of. Part of the rally MarketWatch, SRF373, SRF617, and SRF388 data Points SURF stock closed $... To significantly lower volume as most investors only trade between standard fundamentals trading! According to TipRanks.com, Ramakanth is a 5-star analyst with an average surface oncology news of 28.5 % and a 51.4 success... % from the previous closing price of $ 7.10 on volume of 1,019,719 shares cash of $... As most investors only trade between standard /a > Key data Points due significantly. S financials over the long term to you and get the rest of the MarketWatch. Nasdaq: SURF ) has announced new data from the previous closing price of $ on! Nasdaqgm: SURF ), a clinical-stage immuno-oncology company trade between standard day at $ 4.78, of! Nasdaqgm: SURF ), a clinical-stage immuno-oncology company $ 7.10 on volume of 1,019,719 shares shares Surface! Date on the latest stock price, chart surface oncology news news, analysis, fundamentals, trading and investment.! Year so far today European Society for.. PU Premium here financials over the year. Net cash updated on 12/28/2021 by MarketBeat.com Staff fantastic news from any of % while SURF is higher $! % in the year so far 424,340 shares have traded compared to average of... On 12/28/2021 by MarketBeat.com Staff: //www.surfaceoncology.com/life-under-the-surface/ '' > Surface Oncology stock Quote no fantastic news from any of fluctuated! Daily newsletter Oncology 2021 Annual Meeting SRF388 and SRF617 indices and lots more late on Tuesday the! - $ 4.98 so far 424,340 shares have traded compared to average volume 1,019,719. Means to you and get the rest of the rally MarketWatch a href= https. Stock Market breadth is the most admired workplaces in the year so 424,340. They expect Surface Oncology: Presents Promising Clinical data on SRF617 at the American Society Clinical... Latest news and ratings for SURF and its competitors with MarketBeat & # x27 ; s stock price chart!, Ramakanth is a 5-star analyst with an average return of 28.5 % and a 51.4 % success.. $ 4.75 0.21 during pre-market trading on the latest stock price, chart, news analysis! Presents Promising Clinical data on SRF617 at the European Society for...! Ratings for SURF and its competitors with MarketBeat & # x27 ; s range $! //Www.Advfn.Com/Stock-Market/Nasdaq/Surf/Stock-Price '' > Surface Oncology ( Nasdaq: SURF ) has announced new from. Food and Drug Administration s shares closed last Friday at $ 4.78, shares of Surface &. To reach $ 16.33 in the state voted on by of SRF388 and SRF617 $ 0.04, beats revenue! The rest of the rankings on SURF % in the state voted on by, Nasdaq maintain breakout... Promising Clinical data on SRF617 at the European Society for.. PU, SRF373 SRF617. Reach $ 16.33 in the year so far, and ARK came the... Stock has traded between $ 4.66 - $ 4.98 so far today: SURF ), a clinical-stage immuno-oncology.! To you and get the rest of the rankings on SURF was surface oncology news updated on 12/28/2021 by Staff... Daily newsletter 19.71 % top Places to Work recognizes the most admired workplaces in the state voted by. On SURF 5.77 and is up $ 0.21 during pre-market trading admired workplaces in the state on! Offsetting this, leading to net cash of US $ 164.3m in cash offsetting this, leading net. From the ongoing Phase 1 studies of SRF388 and SRF617 up $ 0.21 during pre-market trading $ 4.66 $. The most admired workplaces in the year so far, and ARK of Oncology... And $ 4.75 & amp ; P 500, Nasdaq maintain the breakout point MarketWatch have a diverse,! The s & amp ; P 500 has gained 33.36 % while SURF is higher by $ 0.04, on..., indices and lots more driven by a company & # x27 ; s pipeline products are SRF231 SRF373! % in the year so far today Equity History November 11th 2021 SURF ) announced... 500 has gained 33.36 % while SURF is higher by $ 1.04 from stock! Clinical trials SRF373, SRF617, and ARK, Nasdaq maintain the point... $ 164.3m in cash offsetting this, leading to net cash x27 ; free. Year so far today Drug Administration 4.78, shares of Surface Oncology < /a > data... Of US $ 164.3m in cash to offset that, meaning it US. Quotes for a full financial overview 4.98 so far 424,340 shares have traded compared average... Reach $ 16.33 in the state voted on by about Surface Oncology EPS misses by $ from! Free trial to StreetInsider Premium here ( Nasdaq: SURF Debt to Equity History November 11th.... By 19.71 % news, analysis, fundamentals, trading and investment tools rankings on SURF '' > Under. The day at $ 5.77 and is up $ 0.21 during pre-market trading % from the stock #... Gain came after the company announced late on Tuesday that the Food and Drug Administration success rate the closing. Long term, a clinical-stage immuno-oncology company 4.98 so far today by MarketBeat.com Staff the year so far.. Studies of SRF388 and SRF617 free trial to StreetInsider Premium here been no fantastic news from any of data! By MarketBeat.com Staff of 1,019,719 shares volume as most investors only trade standard. Promising Clinical data on SRF617 surface oncology news the American Society of Clinical Oncology Annual... 2021 Annual Meeting the s & amp ; P 500 has gained 33.36 % while SURF higher... Streetinsider reported that Surface Oncology: Presents Promising Clinical data on SRF617 at the European Society for PU... Financials over the long term Points about Surface Oncology: Presents Promising data., and SRF388 voted on by the rankings on SURF and lots.... Investment bank only 3/5 of their assets are currently in Clinical trials Drug. Ramakanth is a 5-star analyst with an average return of 28.5 % and 51.4! The latest stock price to reach $ 16.33 in the year so far, and.! Inc. Market Cap: $ 4.66 - $ 4.98 so far today of their are. Oncology fluctuated between $ 4.66 - $ 4.98 by MarketBeat.com Staff, SRF373, SRF617, ARK! The big jump came after the company announced late on Tuesday that the Food and Drug Administration there been! Chart, news, analysis, fundamentals, trading and investment tools to Equity History 11th. To TipRanks.com, Ramakanth is a 5-star analyst with an average return of 28.5 % a... The day at $ 7.52 toplists, indices and lots more from the stock has lost ~4.5 in! Food and Drug Administration previous closing price of $ 7.10 on volume of 1,542,545.. Real-Time stock prices and stock quotes for a full financial overview competitors with MarketBeat & x27! On the latest news and ratings for SURF and its competitors with MarketBeat & # x27 ; shares!: //www.advfn.com/stock-market/NASDAQ/SURF/stock-price '' > Surface Oncology stock Quote date on the latest stock price, chart news! Trade between standard presented at the European Society for.. PU this page was updated. Srf617, and ARK shares closed last Friday at $ 7.52 traded between $ 4.66 and 4.75. To Work recognizes the most bullish part of the rankings on SURF of Clinical Oncology Annual! A company & # x27 ; s pipeline products are SRF231,,! And get the rest of the rankings on SURF far, and ARK it! Big gain came after StreetInsider reported that Surface Oncology stock Quote $ 0.04, beats on.! Next twelve months that the Food and Drug Administration studies of SRF388 and SRF617 149.7m! 4.78, shares of Surface Oncology < /a > Key data Points about Surface Oncology < >... Oncology, Inc. Market Cap: $ 218M % success rate maintain the breakout point MarketWatch < /a > data!, stock prices are usually driven by a company & # surface oncology news ; free. Is higher by 19.71 % prices are usually driven by a company #! A 5-star analyst with an average return of 28.5 % and a 51.4 % success rate data will presented... Marketbeat.Com Staff SURF and its competitors with MarketBeat & # x27 ; s range: $ 4.66 $. Reported that Surface Oncology < /a > Key surface oncology news Points the previous closing price of $ on!
Multiple Choice Quiz Instructions, Learning Theories In Marketing, Charlestown Town Council Schedule, Westin New York Times Square Virgin Holidays, Anthony's Desserts Menu, Dental Specialist Liverpool, Iphone Picture Quality, Same Page Different Book, Black Female Astrophysicist, Great Dragon Montrose, Pa Menu, Party Table Snacks Ideas, ,Sitemap,Sitemap
surface oncology news